| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 1
| Issue : 6 | Page : 28-30 |
|
|
The bacteremia antibiotic length actually needed for clinical effectiveness research program (balance.ccctg.ca)
Nick Daneman, Asgar Rishu, Robert Fowler
Sunnybrook Hospital, the University of Toronto, Toronto, Ontario, Canada
Correspondence Address:
Robert Fowler
MDCM, MS (Epi), FRCP(C), 2075 Bayview Avenue, Room D478, Sunnybrook Hospital, Toronto, Ontario
Canada
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2543-1854.219135
|
|
|
A multitude of global health organizations have declared antimicrobial resistance a threat to health, based on rapidly increasing resistance rates and declining new drug development. Up to 30%–50% of antibiotic use is estimated to be inappropriate, and excessive durations of treatment are the greatest contributor to inappropriate use. A landmark trial in critically ill patients with ventilator-associated pneumonia showed that mortality and relapse rates were noninferior in patients who received 8 versus 15 days of treatment, but similar evidence is lacking for the treatment of patients with bloodstream infection, which affects 15% of critically ill patients. The Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) research program was initiated to provide evidence-based guidance on this question. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
